Calamos Advisors LLC Boosts Stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Calamos Advisors LLC grew its position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) by 124.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,725 shares of the company's stock after acquiring an additional 13,720 shares during the quarter. Calamos Advisors LLC's holdings in Guardian Pharmacy Services were worth $501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter worth approximately $30,000. Investment Research & Advisory Group Inc. bought a new position in Guardian Pharmacy Services during the fourth quarter valued at $34,000. Stephens Inc. AR purchased a new position in shares of Guardian Pharmacy Services during the 3rd quarter valued at $189,000. Virtu Financial LLC bought a new position in shares of Guardian Pharmacy Services during the 3rd quarter worth $279,000. Finally, Barclays PLC purchased a new stake in Guardian Pharmacy Services in the 3rd quarter worth about $311,000.

Guardian Pharmacy Services Price Performance

NYSE:GRDN traded down $1.00 during trading hours on Friday, hitting $21.24. The stock had a trading volume of 52,489 shares, compared to its average volume of 68,736. Guardian Pharmacy Services, Inc. has a one year low of $14.16 and a one year high of $25.74. The business's 50 day moving average price is $21.96.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($2.19). The business had revenue of $314.39 million during the quarter, compared to analysts' expectations of $303.21 million. Equities research analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Insider Transactions at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, Director Steven D. Cosler purchased 7,000 shares of the business's stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $21.22 per share, for a total transaction of $148,540.00. Following the completion of the transaction, the director now directly owns 17,713 shares in the company, valued at approximately $375,869.86. This represents a 65.34 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Analyst Upgrades and Downgrades

GRDN has been the subject of a number of research reports. Stephens began coverage on shares of Guardian Pharmacy Services in a research report on Tuesday, October 22nd. They set an "overweight" rating and a $21.00 target price for the company. Truist Financial boosted their target price on shares of Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, November 15th. Finally, Raymond James began coverage on Guardian Pharmacy Services in a report on Monday, October 21st. They issued an "outperform" rating and a $21.00 price target for the company.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.